WallStreetZenWallStreetZen

How to Buy Catalent Stock

Catalent Inc

Catalent is a pharmaceutical company located in New Jersey, United States, which is part of the Healthcare sector, and is traded under the ticker CTLT on the NYSE exchange.

Catalent stock last closed at $62.64, down 3.11% from the previous day, and has decreased 40.33% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.05 percentage points. Catalent stock is currently +53.94% from its 52-week low of $40.69, and -45.69% from its 52-week high of $115.34.

There are currently 180.09M shares of CTLT outstanding. The market cap of CTLT is $11.28B. In the last 24 hours, 2.23M CTLT shares were traded.

How to Buy Catalent Stock

Not sure how to invest in Catalent stock? Here's how.
  1. Decide where to buy Catalent stock: You need to decide on an online brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you determine where to buy Catalent stock.
  2. Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
  3. Deposit money your brokerage account: Pick your payment method and add your information.
  4. Research Catalent stock: The Catalent ticker symbol is CTLT. Is Catalent stock a good investment? Should you buy shares of CTLT? How do CTLT's underlying business fundamentals look? Do top analysts think Catalent is a good buy? Why has CTLT's stock price moved recently? (Hint: Our stock research tools can help you understand if CTLT is a good stock to buy).
  5. Execute your CTLT trade: Decide if you will purchase CTLT shares at the current market price or use a limit order to purchase CTLT shares at a specific price.
  6. Get updates on your CTLT position: Create a watchlist to important updates regarding your position in Catalent stock.

Step 1: Decide where to buy Catalent stock

You need an online brokerage account in order to access the NYSE market and buy CTLT shares.

A brokerage account is an investment account that allows you to buy and sell a number of financial instruments, such as stocks, bonds, mutual funds, and ETFs.

Our recommended brokerage: eToro

Based on our experience, eToro is the best online stock brokerage. eToro gives you:

  • You can invest in stocks with 0% commissions: Invest without paying trading commissions.
  • Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
  • Access to world markets: From Tech to Healthcare, New York to Tokyo — you can fill your portfolio with stocks from the world's top stock exchanges.
  • Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
  • Security: eToro is a regulated and licensed fintech leader.
  • Buy other assets: Such as ETFs and cryptos.

Get $10 towards your purchase of shares by creating an account with eToro now.

Open eToro Account

Step 2: Sign up for a brokerage account

Now that you've selected your brokerage, you'll need to fill out some personal info so you are able to buy CTLT stock today.

How to Create a New Brokerage Account on eToro

  1. Click here to get started.
  2. Input your personal data to create your new trading account.
  1. Send your info by pressing the "Create Account" button.
Get started with eToro today

Step 3: Deposit money your brokerage account

Now that you've created your account on one of the most highly reviewed stock apps, your next step is to transfer the money for your investment:

Check out this video walkthrough to see the process of transferring funds into your investment account.

Get started with eToro today

Step 4: Research Catalent stock

Once you have identified the best place to buy Catalent stock, it's very important to evaluate their stock prior to investing, so you can understand the risk as well as the opportunity.

Catalent quick stats

CTLT Price
$62.64
1w %
-12.02%
1y %
-40.33%
5y %
58.98%
P/E
27.59x
P/B
2.3x
P/S
2.37x
PEG
0.8x
Revenue
$4.76B
Earnings
$409.00M
Fore. Rev. Growth
10.29%
Fore. Earn. Growth
34.53%
Market Cap
$11.28B
Next Earnings
May 1, 2023
Next Dividend
N/A

Catalent Fundamentals

WallStreetZen was built to help average investors do better fundamental analysis quickly.

You can see all of the due diligence checks on CTLT's stock page.

Is CTLT stock undervalued or overvalued?

Investors use a variety of different financial metrics, analyses, models, and charts to gauge CTLT's intrinsic value.

Using relative valuations metrics:

  • CTLT may be overvalued based on its P/E ratio of 27.59x, relative to Drug Manufacturers - Specialty & Generic industry P/E ratio of 17.72x
  • CTLT could be overvalued based on its P/B ratio of 2.3x, relative to Drug Manufacturers - Specialty & Generic industry P/B ratio of 1.77x
  • CTLT could be undervalued based on its PEG ratio of 0.8x

You can access more valuation analysis on CTLT's stock here.

CTLT Financial Health Overview

Pros:

  • CTLT has $470.00M in cash and short term investments. This is enough to cover its annual cash burn of $364.00M.
  • There are more short-term assets than short-term liabilities on the CTLT balance sheet.
  • Total CTLT debt is lower than 5 years ago, relative to shareholder equity.
  • CTLT has cash burn of 364000000. It has sufficient cash and short-term investments to cover this for at least one year.

Cons:

  • CTLT profit margin has gone down from 12.6% to 8.6% in the past year.
  • CTLT has a relatively high debt to equity ratio of 1.27.
  • There are more long-term liabilities than short-term assets on the CTLT balance sheet.

Do Wall Street analysts think it's a good time to buy CTLT stock

Out of 9 sell side analysts who give ratings on CTLT, the consensus analyst rating on Catalent is a Buy

Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.

Most Recent CTLT Analyst Recommendations

Justin Bowers, a bottom 12% analyst from Deutsche Bank maintains CTLT with a hold rating and raises their CTLT price target from $65.00 to $79.00, on Feb 9, 2023.

Tejas Savant, a bottom 9% analyst from Morgan Stanley maintains CTLT with a strong buy rating and raises their CTLT price target from $81.00 to $85.00, on Feb 9, 2023.

Evan Stover, a top 34% analyst from Baird maintains CTLT with a buy rating and raises their CTLT price target from $75.00 to $82.00, on Feb 8, 2023.

Luke Sergott, a bottom 2% analyst from Barclays maintains CTLT with a strong buy rating and raises their CTLT price target from $58.00 to $82.00, on Feb 8, 2023.

David Toung, a top 22% analyst from Argus Research downgrades CTLT to a hold rating, on Nov 7, 2022.

You can dive deeper into what analysts are projecting on the Catalent stock forecast page.

CTLT Technicals

SMA10
67.31
SMA20
68.49
SMA50
63.08
SMA100
54.65
SMA200
75.17
MACD
0.28
MACD Signal
1.46
MACD Histogram
-1.18
RSI
41.14
Stochastic %K
9.78
Stochastic %D
17.6
StochRSI %K
1.03
StochRSI %D
2.73

Is CTLT Making Money?

Last year, CTLT earnings were $409.00M. Over the last 5 year, CTLT's earnings have gone up by 31.38% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 15.74%.

Last year, CTLT revenue was $4.76B. Over the last 5 year, CTLT's revenue has increased by 15.65% per year. This was slower than the Drug Manufacturers - Specialty & Generic industry average of 19.6%.

Dive into CTLT's earnings and revenue performance here.

Who is buying/selling CTLT?

Over the last year, insiders at CTLT have sold more shares than they have bought.

Ricky Hopson, Pres. Clinical Dev Supply Div of CTLT, was the latest CTLT insider to sell. They sold $31,738.48 worth of CTLT shares on Jan 23, 2023.

Learn more about who owns CTLT stock here.

Can I rely on CTLT as an income stream?

No, Catalent doesn't provide an income stream by paying out dividends.

Get analysis from other traders

One of the major reasons eToro is our top-rated brokerage is because of its social trading community.

Click below to learn what other community members have to say.

Step 5: Execute your CTLT trade

You have two main order types:

  • Market order: A market order is an order to buy or sell a security at the best price on the market.
    Market orders are mostly sufficient.
  • Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
    If you want to be certain you're buying or selling at a given price, use a limit order.

Press the Open button and eToro will place the order.

If you want more help with investing in stocks on eToro, click the how to video below:

Open eToro Account

Step 6: Get updates on your CTLT position

Now that you own some CTLT shares, you'll want to stay up-to-date on your shares.

Create a watchlist to get notified of the latest news about your CTLT stock.

CTLT Feed

How to Buy Stock in Catalent

To summarize, here are the 6 steps you need to take to buy Catalent stock right now:

  1. Decide where to buy Catalent stock
  2. Sign up for a brokerage account
  3. Deposit money your brokerage account
  4. Research Catalent stock
  5. Execute your CTLT trade
  6. Get updates on your CTLT position

If you need a place to buy stocks, eToro is our recommended venue.

Get Started with eToro Today

If you would like to keep track of your investment in Catalent, hit the button below to create your watchlist.

NYSE: CTLT
$62.64-2.01 (-3.11%)
Updated Mar 23, 2023
Open eToro Account
NYSE: CTLT
$62.64-2.01 (-3.11%)
Updated Mar 23, 2023
Open eToro Account

FAQ

How much does it cost to buy one Catalent share?

As of Mar 23, 2023, it costs $62.64 to buy one share of Catalent stock.

Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.16 shares of CTLT.

Get Started with eToro Today

Is now a good time to buy Catalent stock?

According to 9 Wall Street analysts who monitor Catalent, their consensus recommendation is to buy Catalent stock.

What is the best way to buy Catalent stock?

One way to place an order for Catalent stock is with a brokerage account.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.